Le Lézard
Classified in: Health, Science and technology, Business
Subject: LIC

GV20 Therapeutics Joins NVIDIA Inception to Develop AI Models for Drug and Target Discovery


CAMBRIDGE, Mass., March 12, 2024 /PRNewswire/ -- GV20 Therapeutics, a clinical stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics for cancer, announced today that it has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements.

GV20 Therapeutics will leverage the resources provided by NVIDIA Inception to develop new AI models for drug discovery, focused on novel therapeutic antibodies. The company will use the NVIDIA BioNeMo cloud service to continue scaling and refining the computational arm of the STEAD platform for accelerated target and antibody discovery, which also includes research utilizing genomics and molecular dynamics simulation. The incorporation of NVIDIA BioNeMo into the existing STEAD platform will expedite progress and new innovations to the platform.

"We are thrilled to be part of NVIDIA Inception," said Shirley Liu, CEO of GV20 Therapeutics. "We expect the resources provided by the program to help enable us to accelerate the improvement of our STEAD discovery platform and to continue identifying exciting novel cancer drug targets, like IGSF8, and therapeutic antibodies."

ABOUT GV20 THERAPEUTICS

At GV20 Therapeutics, our mission is to develop a differentiated pipeline of innovative antibody therapeutics to transform the treatment of cancer. We leverage our in-house STEAD platform (Simultaneous Target Evaluation and Antibody Discovery), which integrates AI, genomics, and disease biology to identify novel drug targets and create next-generation therapies against these targets. Our lead program, GV20-0251, is in Phase 1 for the treatment of solid tumors targeting IGSF8, a promising target for cancer immunotherapy. GV20 is headquartered in Cambridge, MA. 

To learn more about GV20, please visit https://gv20tx.com/ and follow the company on LinkedIn.

Business Contact
Ying Gong, Ph.D., CBO
[email protected] 

GV20 Therapeutics logo (PRNewsfoto/GV20 Therapeutics)

SOURCE GV20 Therapeutics


These press releases may also interest you

at 08:15
Masimo Nominee Christopher Chavez Would Bring Fierce Independence, Exemplary Medtech CEO Experience to Masimo Board
Masimo Corporation ("Masimo" or the "Company") today issued a letter to stockholders in connection with the Company's 2024 Annual Meeting of Stockholders. The letter highlights the fierce independence and deep medtech experience of nominee...

at 08:15
Nicholas Cumins Takes Charge as CEO of Bentley Systems, Ushering in a New Era
Following the CEO transition plan previously announced by Bentley Systems, Incorporated , Nicholas Cumins today takes charge as CEO. Cumins succeeds Greg Bentley, the eldest of the five brothers who founded Bentley Systems, who becomes Executive...

at 08:15
KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug (IND) for Oncolytic Immunotherapy VET3-TGI for Solid Tumors
KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced that the FDA has cleared the Investigational New Drug (IND) application for the STEALTH-001 study...

at 08:15
dunnhumby Unveils AI-powered Assortment Solution for Localized Assortments Based on Customer Preferences
dunnhumby, the global leader in customer data science, today launched its next-generation assortment solution, harnessing cutting-edge AI to revolutionize how retailers select products. New features unveiled in dunnhumby Assortment include:...

at 08:15
Perfect Corp. Partners with NAO-ART to Power First-of-its-Kind Generative AI Wig Virtual Try-On Experience in Japan
Perfect Corp., the leading AI and AR beauty and fashion technology provider and developer of ?Beautiful AI' solutions, proudly announces its collaboration with NAO-ART, a subsidiary of the Art Nature Group and a provider of ready-to-wear wig brands...

at 08:11
Cogitate Names Chief Technology Officer
Cogitate announces the appointment of Lava Jois as Chief Technology Officer (CTO), reporting to CEO and Co-founder, Arvind Kaushal. Lava will lead the development and implementation of Cogitate's DigitalEdge Insurance solution suite, spearheading...

More news about Science and technology...


News published on and distributed by: